Companies › LEO Pharma
3 active drug programs in 8 registered trials: 4 Phase 2, 3 Phase 3, 1 Phase 4; Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Spesolimab IL36 receptor antagonist | IL36R, IL1RAP | Phase 4 | Generalized Pustular Psoriasis; Pyoderma Gangrenosum | Sep 2027 |
| Delgocitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; Vitiligo | Dec 2026 |
| Tralokinumab Interleukin-13 inhibitor | IL13 | Phase 3 | Atopic Dermatitis | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06013969 | Spesolimab | Phase 4 | Generalized Pustular Psoriasis | Immunology | May 2026 |
| NCT07013201 | Delgocitinib | Phase 2 | Palmoplantar Pustulosis | Immunology | Dec 2026 |
| NCT07487948 | Delgocitinib | Phase 2 | Central Centrifugal Cicatricial Alopecia | Immunology | Apr 2027 |
| NCT07820098 | Delgocitinib | Phase 2 | Vitiligo | Immunology | Apr 2027 |
| NCT03886246 | Spesolimab | Phase 2 | Generalized Pustular Psoriasis | Immunology | Sep 2027 |
| NCT06624670 | Spesolimab | Phase 3 | Pyoderma Gangrenosum | Immunology | Nov 2027 |
| NCT07335588 | Delgocitinib | Phase 3 | Lichen Sclerosus | Immunology | Mar 2028 |
| NCT06311682 | Tralokinumab | Phase 3 | Atopic Dermatitis | Immunology | Apr 2028 |
Alfasigma Galderma R&D Sun Pharma Japan Integrative Skin Science and Research Alumis
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.